Hemolysis in Patients With Hereditary Spherocytosis (HS)
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In the present study the investigators are going to explore the oxidative status of HS-RBC and its contribution to hemolysis
| Condition | Intervention |
|---|---|
|
Hereditary Hemolysis |
Other: fermented papaya preparation (FPP) |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Oxidative Stress Contributes to Hemolysis in Patients With Hereditary Spherocytosis (HS) and Can be Ameliorated by Fermented Papaya Preparation (FPP) |
- ROS, reduced glutathione (GSH) and lipid peroxides will be measured in RBC [ Time Frame: year ] [ Designated as safety issue: Yes ]ROS, reduced glutathione (GSH) and lipid peroxides will be measured in RBC following incubation with with 100 μM 2'-7'-dichlorofluorescin diacetate, 40 μM [1-(4-chloromercuryphenyl-azo-2-naphthol)] and fluor-DHPE, respectively for ROS [8] and with mercury orange for GSH [9]. After being washed twice, the cells will be resuspended in PBS and analyzed by flow cytometry .
- Hemolysis [ Time Frame: year ] [ Designated as safety issue: Yes ]Hemolysis will be assayed by suspending 3 ml of packed RBC in PBS or in the autologous plasma and overnight incubation in the presence of various concentrations of antioxidants such as fermented papaya preparation (FPP)
| Estimated Enrollment: | 15 |
| Study Start Date: | September 2010 |
| Estimated Study Completion Date: | September 2011 |
| Estimated Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: Patients with Hereditary Spherocytosis
All patients should have clinical and laboratory findings, consistent with mild to severe HS, diagnosed on the basis of spherocyte morphology, elevated MCHC (33-38 g/dl), with a mean value of (35.47 g/dl), increased osmotic fragility , splenomegaly and non-immune mediated hemolysis.
|
Other: fermented papaya preparation (FPP)
Hemolysis will be assayed by suspending 3 ml of packed RBC in PBS or in the autologous plasma and overnight incubation in the presence of various concentrations of antioxidants such as fermented papaya preparation (FPP) at 37oC in humidified atmosphere of 5% CO2 in air (10). Following 5 min centrifugation at 800 rpm, the supernatants will collected for Hb determination by measuring the absorbance at 540 nm.
|
Detailed Description:
The oxidative status of cells, which is determined by the balance between pro-oxidants, such as the reactive oxygen species (ROS), and antioxidants, is a major regulator of cellular functions. Impaired balance between pro- and antioxidants causes oxidative stress which may result in oxidation of proteins, lipids and DNA with the final outcome of premature cell aging and apoptosis [1,2]. Oxidatively stressed red blood cell (RBC) have been observed in various congenital and acquired hemolytic anemias, including thalassemia, sickle cell anemia, congenital dyserythropoietic anemia, G6PD deficiency and paroxysmal nocturnal hemoglobinuria (PNH) as well as in myelodysplastic syndrome (MDS). Although the primary etiology is different in these anemias, oxidative stress mediates several of their pathologies, mainly hemolysis [3].
Hereditary Spherocytosis (HS) is a genetic disorder of the RBC skeleton with primary deficiency in spectrin, ankyrin-1, band 3 or protein 4.2 associated with chronic hemolytic anemia [4]. Secondary protein deficiencies resulting from oxidative stress are often observed and may be involved in the clinical manifestations of the disease [5].
Eligibility| Ages Eligible for Study: | 5 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- patients > 5 years
- with documented family history of HS
- patients should have clinical and laboratory findings, consistent with mild to severe HS, diagnosed on the basis of spherocyte morphology, elevated MCHC (33-38 g/dl), with a mean value of (35.47 g/dl), increased osmotic fragility , splenomegaly and non-immune mediated hemolysis.
Exclusion Criteria:
- non
Contacts and Locations| Contact: Ghoti Hossam, doctor | 035028110 | drghoti123@yahoo.com |
| Israel | |
| Wolfsson Medical Center | Not yet recruiting |
| Holon,, Israel,, Israel | |
| Contact: GHOTI HOSSAM, doctor 970-35028110 drghoti123@yahoo.com | |
| Principal Investigator: | GHOTI HOSSAM, doctor | HEMATOLOGY DEPARTMENT ON WOLFSSON MEDICAL CENTER |
More Information
No publications provided
| Responsible Party: | Dr. Ghoti Hossam, Organization: hematology department on Wolfsson Medical Center |
| ClinicalTrials.gov Identifier: | NCT01201174 History of Changes |
| Other Study ID Numbers: | SH-01CTIL |
| Study First Received: | September 12, 2010 |
| Last Updated: | September 13, 2010 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Wolfson Medical Center:
|
Hemolysis in Patients with Hereditary Spherocytosis with documented family history of HS. spherocyte morphology, splenomegaly and non-immune mediated hemolysis. |
Additional relevant MeSH terms:
|
Hemolysis Spherocytosis, Hereditary Pathologic Processes Anemia, Hemolytic, Congenital |
Anemia, Hemolytic Anemia Hematologic Diseases Genetic Diseases, Inborn |
ClinicalTrials.gov processed this record on May 16, 2013